# Cochrane

# Trusted evidence.

# Informed decisions.

# Library

# Better health.

# Cochrane Database of Systematic Reviews

# Stallmach 2022

# Study name

Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial

# Methods

Multicenter RCT conducted in Germany

# Participants

# Inclusion criteria

- Ages 18–75 years
- Prior endoscopically confirmed active UC of ≥ 6 months and disease extent of ≥ 15 cm from anal verge
- Active disease (Mayo score 4–10 and Mayo Endoscopic subscore > 1) at study entry
- May be receiving 1 of the following drugs:
- oral 5-ASA compounds with stable prescribed dose for ≥ 4 weeks prior to randomization and the first 12 weeks after randomization
- azathioprine, 6-mercaptopurine, or methotrexate with stable prescribed dose for 8 weeks prior to randomization and the first 12 weeks after randomization
- oral corticosteroid therapy (prednisone at stable dose ≤ 20 mg/day or budesonide at stable dose of ≤ 9 mg/day) if prescribed dose has been stable for 2 weeks prior to randomization
- topical therapy (foams, enema) with mesalazine or budesonide if prescribed dose has been stable for 2 weeks prior to randomization
- Complete vaccination against SARS-CoV-2 as recommended by the Standing Committee on Vaccination at the Robert Koch Institute
- Ability to understand and willingness to sign informed consent document and comply with protocol

# Exclusion criteria

- CD or indeterminate colitis or proctitis alone
- Clinical emergencies requiring emergent management (e.g. acute abdomen: bowel obstruction, perforation or abscess (or both), previous bowel surgery)
- Concurrent gastrointestinal infections or other causes of diarrhea
- Congenital or acquired immunodeficiency, severe comorbidities (e.g. diabetes mellitus, cancer, systemic lupus, decompensated cirrhosis, recent malignancy in last 3 years)
- Negative EBV/CMV serology
- Pregnancy
- Inability or unwillingness to undergo colonoscopy
- Previous treatment with anti-TNF, integrin, or interleukin-12/interleukin-23 antibodies within last 8 weeks
- Previous treatment with calcineurin or JAK inhibitors within last 4 weeks
- Systemic antibiotic use within the last 8 weeks
- Participation in clinical trial within last 3 months
- History of FMT or FMFT
- Probiotic use within 14 days of study start date
- Not ensuring frozen storage (−15 ± 5 °C) of capsules
- Medical conditions or circumstances that interfere with appreciation of the nature, significance, scope, and possible consequences of the clinical trial; signs of non-compliance

# Interventions

# Experimental arm

n = 58

- Classical FMT 5 capsules orally twice daily, 5 days per week for weeks 1–12

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.